

POLICY NAME	Synagis (palivizumab)	POLICY #	2325P
--------------------	-----------------------	-----------------	-------

Criteria

Coverage Criteria for diagnosis of Congenital Airway Abnormality or Neuromuscular Condition

- ☐ Documentation of nerves and muscular disorder or congenital abnormality that impairs the ability to cough up mucus from the upper lungs because of ineffective cough
- ☐ Age 12 months or younger

Coverage Criteria for diagnosis of Congenital Heart Disease (CHD)

- ☐ Documentation of CHD hemodynamically significant
- ☐ Age 12 months or younger

Coverage Criteria for diagnosis of Chronic Lung Disease (CLD)

- ☐ Age 24 months or younger
- ☐ Documentation that patient has received medical treatment for CLD in the 6 months prior to RSV season (medical treatment may include oxygen, bronchodilators, diuretics, or chronic corticosteroids)

Coverage Criteria for diagnosis of Prematurity

- ☐ Gestational age of 28 weeks 6 days
- ☐ Chronological age at the start of RSV season of < 12 months

Exclusion Criteria – Any of the following prevents coverage

- ☐ Patients who were already vaccinated against RSV with Beyfortus are not recommended to receive Synagis as well